The effect of kidney transplantation on left ventricular remodeling and global diastolic strain rate in end-stage renal disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Background: Diastolic dysfunction is an early marker of cardiac pathology in end-stage kidney disease (ESKD) patients. The ratio of transmitral filling velocity (E) to early diastolic strain rate (E/e'sr) is a novel non-invasive marker of early left ventricular (LV) filling pressure obtained using two-dimensional speckle tracking echocardiography (2DSTE). Methods: In a prospective cohort of kidney transplant (KTX) recipients with echocardiograms performed pre-transplant we obtained repeat echocardiograms at 6 months following transplant. All echocardiograms were analyzed using 2DSTE where E/e'sr and global longitudinal strain were obtained. Paired tests were used to assess changes to cardiac structure and function following KTX. Results: A total of 33 patients were included in the study (mean age was 46.6 ± 13.7 years and 42% were males). The primary causes of ESKD in the cohort were glomerular disease (33%), hypertension (30%), and polycystic kidney disease (12%). The median (IQR) time spent on dialysis was 5.4 years [2.9, 7.7 years]. A reverse remodeling of the LV was observed following KTX as LV mass decreased (189.2 ± 57.5 g vs 171.1 ± 56.8 g, P = 0.014). LV filling pressure decreased as assessed by E/e'sr (103.7 ± 51.1 cm vs 72.6 ± 35.5 cm, P = 0.009). E to early diastolic mitral annular tissue velocity (E/e’) did not change following KTX (9.9 ± 4.5 vs 10.3 ± 4.1, P = 0.54). Additionally, both LV internal diastolic and systolic diameter decreased significantly. Conclusion: Reverse cardiac remodeling following KTX was observed as improvements in LV mass and LV dimensions. LV filling pressure improved as assessed by E/e'sr decreased following KTX, whereas E/e’ did not change.

OriginalsprogEngelsk
TidsskriftEchocardiography
Vol/bind38
Udgave nummer11
Sider (fra-til)1879-1886
ISSN0742-2822
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
This work was supported by a grant from the Lundbeck Foundation to UCSF to fund Lundbeck Foundation Clinical Research Fellowship for MHL. Furthermore, MHL received a research grant from Gentofte & Herlev Hospital. The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the article. TBS reports receiving research grants from Sanofi Pasteur and GE Healthcare, is a Steering Committee member of the Amgen financed GALACTIC‐HF trial, on advisory boards for Sanofi Pasteur and Amgen, and speaker honorariums from Novartis and Sanofi Pasteur.

Publisher Copyright:
© 2021 Wiley Periodicals LLC

ID: 286317146